Children with relapsing multiple sclerosis (MS) had an 82% lower relapse rate when treated with a drug currently only licensed for use in adults.
The Irish arm of pharma giant Novartis last year increased its profits by 31% on the back on strong performance by a number of brands.
Hundreds of patients are being denied fast access to vital stroke, multiple sclerosis, bipolar disorder and hepatitis C drugs because the HSE is “rationing” money for new treatments.
Thursday, September 24, 2020 - 10:00 PM
Thursday, September 24, 2020 - 6:00 PM
Thursday, September 24, 2020 - 9:00 PM